Compare SOPH & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | NBTX |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | Switzerland | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 1.8B |
| IPO Year | 2021 | 2018 |
| Metric | SOPH | NBTX |
|---|---|---|
| Price | $4.89 | $34.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 100.9K | 52.2K |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | $58.17 |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $4.29 |
| 52 Week High | $5.70 | $57.14 |
| Indicator | SOPH | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 42.89 |
| Support Level | $4.56 | $30.15 |
| Resistance Level | $5.44 | $41.89 |
| Average True Range (ATR) | 0.31 | 2.14 |
| MACD | -0.01 | -0.47 |
| Stochastic Oscillator | 31.06 | 34.27 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.